Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-3864086 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| healthy volunteers | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-3864086 | DRUG | The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well. |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * healthy male volunteers * no drug history * no other medication for 28 pre-dose Exclusion Criteria: * age below 21 years * age above 55 years
PF-3864086 is an investigational small molecule being developed for the treatment of pain. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its safety, tolerability, and pharmacokinetic profile in healthy subjects.
PF-3864086 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in Phase 1 clinical development for the treatment of pain.
PF-3864086 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of pain, with one completed Phase 1 clinical trial evaluating its safety, tolerability, and pharmacokinetics.
PF-3864086 has one completed clinical trial, identified as NCT00747058. This Phase 1 study investigated the safety, toleration, and pharmacokinetics of single oral doses of PF-03864086 in healthy male subjects. The trial enrolled 28 participants and was conducted in Belgium.
Yes, PF-3864086 is the same drug as PF-03864086. The clinical trial NCT00747058 refers to the drug as PF-03864086, while the drug is also known as PF-3864086. Both names refer to the same investigational small molecule being developed for pain.